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Dobutamine as selective b1-adrenoceptor agonist in in vivo
studies on human thermogenesis and lipid utilization
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W. H. M. SARIS, AND M. A. VAN BAAK
Nutrition Toxicology and Environment Research Institute Maastricht,
Department of Human Biology, Maastricht University, 6200 MD Maastricht, The Netherlands
Schiffelers, S. L. H., V. J. A. van Harmelen, H. A. J. de
Grauw, W. H. M. Saris, and M. A. van Baak. Dobutamine
as selective b1-adrenoceptor agonist in in vivo studies on
human thermogenesis and lipid utilization. J. Appl. Physiol.
87(3): 977–981, 1999.—The use of dobutamine as selective
b1-adrenoceptor agonist in in vivo studies on human thermo-
genesis and lipid utilization was investigated in 20 men. At
2.5, 5, and 10 µg·kg21 ·min21, dobutamine induced significant
increases in energy expenditure, lipid oxidation, and lipoly-
sis. The b1-adrenoceptor antagonist atenolol (bolus: 42.5
µg/kg, infusion: 1.02 µg·kg21 ·min21) blocked all dobutamine-
induced effects on thermogenesis and lipid utilization. All
parameters remained at levels comparable to those during
saline infusion. The dose of atenolol used did not inhibit
b2-adrenoceptor-specific changes in energy expenditure, lipid
oxidation, and lipolysis during salbutamol infusion (85
ng·kg21 ·min21). This indicates that atenolol was specific for
b1-adrenoceptors and did not camouflage concomitant b2-
adrenoceptor stimulation during dobutamine infusion. There-
fore, we conclude that dobutamine can be used as a selective
b1-adrenoceptor agonist at dosages #10 µg·kg21 ·min21 in in
vivo studies on human thermogenesis and lipid utilization.
atenolol; salbutamol; lipid oxidation; lipolysis
THE SYMPATHETIC NERVOUS system plays an important
role in the regulation of human thermogenesis. Sympa-
thetic nervous system activity is mainly stimulated in
response to food digestion and physical exercise but can
also be triggered by cold exposure or pathogenic stimuli.
In response to these stimuli, catecholamines are re-
leased that subsequently induce thermogenesis (14).
This increase in energy expenditure is due to stimula-
tion of both b1- and b2-adrenoceptors of the sympathetic
nervous system (4). a1-Adrenoceptors probably do not
play a role (4, 6, 17). The effect of b3-adrenergic
stimulation on human thermogenesis is, at the mo-
ment, still debatable (4, 11, 23), because the available
agonists appear to be only weak partial agonists in
humans (1). In rodents b3-agonists induce significant
effects, but this might be explained by the pharmacologi-
cal differences between human and rodent b3-adrenocep-
tors (10, 15).
In obese men nonselective b-adrenergic stimulation
leads to a reduced increase in thermogenesis and lipid
utilization compared with in lean men (3). Therefore, it
is interesting to know whether these impaired re-
sponses might be due to a defect in the b1- or the
b2-adrenoceptor. The most selective b1-adrenoceptor
agonist for in vivo use in humans is dobutamine. In
lean healthy volunteers dobutamine increases oxygen
consumption, indicating an increase in thermogenesis
(2, 7), decreases respiratory exchange ratio (RER),
suggesting an increase in lipid oxidation, and increases
plasma glycerol and nonesterified fatty acids (NEFA)
concentrations, indicating an increase in lipolysis (7).
However, both in vitro (15, 16) and in vivo (12, 13)
animal studies have shown that dobutamine also has
a1- and b2-adrenoceptor agonistic properties. Because
a1-adrenoceptors are not important for human thermo-
genesis, their role was not further investigated. The
selectivity of dobutamine for b1- and b2-adrenoceptors
in studies on human thermogenesis and lipid utiliza-
tion was elucidated in this study. Therefore, we evalu-
ated the effect of atenolol, a predominantly b1-adreno-
ceptor antagonist, on dobutamine-induced increases in
energy expenditure, lipid oxidation, and lipolysis. Addi-
tion of atenolol should block all b1-adrenoceptor-medi-
ated effects and reveal all other effects of dobutamine.
In a control test, the selective b1-adrenoceptor-blocking
properties of atenolol at the dose used were verified.
Addition of atenolol should have no effect on the in-
creases in thermogenesis and lipid utilization induced
by the selective b2-adrenoceptor agonist salbutamol.
MATERIALS AND METHODS
Subjects. Twenty lean male volunteers participated in this
study. Mean age and body mass index were 22.0 yr (range:
18–27 yr) and 21.9 kg/m2 (range: 19.4–25.3 kg/m2), respec-
tively. The subjects were healthy and took no medication at
the time of the study. They gave written informed consent
before participating in the study. The study protocol was
reviewed and approved by the Ethics Committee of Maas-
tricht University.
Experimental protocol. The study protocol consisted of four
tests. In the dobutamine test, a 30-min baseline period was
followed by consecutive infusions of 2.5, 5, and 10
µg·kg21 ·min21 dobutamine (selective b1-adrenoceptor ago-
nist; Dobax, Byk, Zwanenburg, The Netherlands), each dose
administered during 30 min. This test intended to measure
all dobutamine-mediated effects. The saline test consisted of
a 30-min baseline period followed by three times a 30-min
period of saline infusion (0.6 ml/min) to study the regular
changes in thermogenesis and associated metabolic processes
over this period of fasting. In the dobutamine plus atenolol
test, dobutamine was given (as described above) in combina-
tion with the b1-adrenoceptor antagonist atenolol (Tenormin,
Zeneca, Ridderkerk, The Netherlands) to reveal possible
b2-adrenoceptor-mediated effects of dobutamine. Therefore, a
priming dose of 42.5 µg/kg atenolol was administered intrave-
nously within 5 min at the start of the baseline period, after
The costs of publication of this article were defrayed in part by the
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which a continuous infusion of atenolol (1.02 µg·kg21 ·min21)
was started for the remainder of the test. The salbutamol plus
atenolol test consisted of a 45-min baseline period, after which
the b2-adrenoceptor agonist salbutamol (Ventolin, GlaxoWell-
come, Zeist, The Netherlands) was given for 90 min at an
infusion rate of 85 ng·kg21 ·min21. During the last 45 min,
atenolol was added to the salbutamol infusion at the same dose
as described above to study possible b2-adrenoceptor-blocking
effects of atenolol. The infusion periods were prolonged during
the last test, because thermogenesis did not reach steady
state within 30 min during salbutamol infusion, as it did
during dobutamine infusion. Twenty subjects participated in
the dobutamine test, 10 subjects in the saline test, 14 subjects in
the dobutamine plus atenolol test, and 10 subjects underwent the
salbutamol plus atenolol test. Each of the 20 subjects participated
in 2 or 3 trials. There were no statistically significant differences
in subject parameters between tests. The study design was single
blind, and the order of tests was randomized.
The subjects came to the laboratory at 8:30 AM, with at
least 2 days between tests. All individuals were fasted for at
least 10 h (overnight) and came to the laboratory by car or by
bus to minimize the amount of physical activity before the
tests. At the beginning of each test, a catheter was inserted
into a forearm vein for drug infusion and blood sampling.
During the tests, energy expenditure and RER were continu-
ously measured, and, at the end of each 30- or 45-min
interval, a blood sample was obtained. For safety reasons the
infusion was stopped when heart rate had increased .30
beats/min and/or mean blood pressure had risen more than 30
mmHg. After these criteria, one subject was not tested at the
highest dose of 10 µg·kg21 ·min21 dobutamine. Room tempera-
ture was kept between 23 and 25°C.
Methods. An open-circuit ventilated-hood system was used
for measurement of whole body energy expenditure and RER.
The volume of air drawn through the hood was measured by a
dry-gas meter (Schlumberger, Dordrecht, The Netherlands),
and the composition of the inflowing and outflowing air was
analyzed by a paramagnetic O2 analyzer (Servomex, Crowbor-
ough, UK) and an infrared CO2 analyzer (Hartmann and
Braun, Frankfurt, Germany). Airflow rate and the O2 and
CO2 concentrations of the inflowing and outflowing air were
used to compute O2 consumption (coefficient of variation
2.4%) and CO2 production (coefficient of variation 3.1%)
on-line every 2 min through an automatic acquisition system
interfaced with a personal computer. Energy expenditure was
calculated according to the formula of Weir (21). Energy
expenditure and RER values were averaged over the last 10
min of each infusion step, during which their values were
stable, and their means were used in the data analysis. Blood
pressure was measured by an automated blood pressure
device (Tonoprint, Speidel & Keller, Jungingen, Germany,
and UA 731, Takeda Medical, Rotterdam, the Netherlands)
during the last 10 min of each period. The mean of four
measurements per interval was computed and used for
further analysis. Heart rate was monitored continuously by
conventional electrocardiogram and was recorded at the end
of every 5-min period. The values over the last 10 min were
averaged and used for further analysis.
Analytic methods. Blood samples for glycerol and NEFA
determination were preserved in sodium-EDTA. All samples
were immediately centrifuged for 1 min at 7,280 g. Plasma
was transferred to microtest tubes, rapidly frozen in liquid
nitrogen, and stored at 270°C until further analysis. Plasma
glycerol concentrations were measured with a glycerol kit
(Boehringer 148270, Mannheim, Germany), and plasma NEFA
concentrations were measured with the NEFA C kit (Wako
NEFA C kit 99475409, Neuss, Germany), both on a Cobas-
Fara analyzer (Roche Diagnostica, Basel, Switzerland). In
each run, standard samples with known concentrations were
included for quality control.
Data analysis. All values are presented as means 6 SE.
The differences in outcome between the dobutamine, the
saline, and the dobutamine plus atenolol tests were analyzed
with a split-block incomplete-block factorial ANOVA. In this
design, categories are made for treatment and subject to
account for missing values. Post hoc testing between studies
was done according to Bonferroni’s inequalities. The effects
within studies were analyzed with repeated-measurements
ANOVA. Post hoc testing between time points was done with
a paired t-test, corrected according to Bonferroni’s inequali-
ties. All statistical tests were performed two sided. P , 0.05
was regarded as statistically significant.
RESULTS
Dobutamine, saline, and dobutamine plus atenolol
tests. Energy expenditure increased significantly dur-
ing dobutamine infusion (P , 0.001) (Fig. 1). During
Fig. 1. Energy expenditure (top) and respiratory exchange ratio
(bottom) during infusion of saline (r; n 5 10 subjects), dobutamine
(n; n 5 20 subjects), or dobutamine plus atenolol (dob1at; k; n 5 14
subjects). Values are means 6 SE. Repeated-measurements ANOVA:
##P , 0.01; ###P , 0.001. Unpaired t-test: dobutamine vs. saline,
*P , 0.05, ***P , 0.001; dobutamine vs. dobutamine plus atenolol:
11P , 0.01, 111P , 0.001.
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saline infusion there was no significant change in
energy expenditure. Simultaneous administration of
atenolol completely prevented the dobutamine-induced
increase in energy expenditure. Energy expenditure
remained at a similar level as during the saline test.
RER decreased significantly in all three tests (dobuta-
mine, saline: P , 0.001; dobutamine plus atenolol: P ,
0.01) (Fig. 1). During the second and third infusion
period of dobutamine, RER was significantly lower
than during the corresponding infusion periods with
saline (both P , 0.001). Atenolol infusion prevented the
more pronounced reduction in RER at the higher
dobutamine dosages. RER decreased to a comparable
level as during saline infusion.
Plasma glycerol and NEFA concentrations increased
significantly with dobutamine (both P , 0.001), saline
(glycerol: P , 0.01, NEFA: P , 0.001), as well as
Fig. 2. Plasma glycerol (top) and nonesterified fatty acid (NEFA)
concentration (bottom) during infusion of saline (r; n 5 10 subjects),
dobutamine (n; n 5 20 subjects), or dobutamine plus atenolol (k; n 5
14 subjects). Values are means 6 SE. Repeated-measurements
ANOVA: ##P , 0.01, ###P , 0.001. Unpaired t-test: dobutamine vs.
saline, *P , 0.05, ***P , 0.001; dobutamine vs. dobutamine plus
atenolol: 11P , 0.01, 111P , 0.001.
Fig. 3. Heart rate (top) and systolic (middle) and diastolic (bottom)
blood pressure during infusion of saline (r; n 5 10 subjects),
dobutamine (n; n 5 20 subjects), or dobutamine plus atenolol (k; n 5
14 subjects). Values are means 6 SE. Repeated-measurements
ANOVA: #P , 0.05, ###P , 0.001. Unpaired t-test: dobutamine vs.
saline, ***P , 0.001; dobutamine vs. dobutamine plus atenolol: 1P ,
0.05, 11P , 0.01, 111P , 0.001; saline vs. dobutamine plus atenolol:
@P , 0.05.
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dobutamine plus atenolol (glycerol: P , 0.01, NEFA:
P , 0.001) (Fig. 2). In all infusion periods glycerol and
NEFA concentrations were significantly higher in the
dobutamine test compared with the saline and dobuta-
mine plus atenolol tests. During atenolol administra-
tion, glycerol and NEFA levels remained similar to
those during saline infusion.
During the last infusion period, heart rate was
significantly higher with dobutamine than with saline
(P , 0.001) (Fig. 3). Heart rate did not change during
saline infusion. Atenolol lowered heart rate at baseline
and completely inhibited the increase in heart rate by
dobutamine. Systolic blood pressure increased signifi-
cantly (P , 0.001), and diastolic blood pressure re-
mained unchanged in the dobutamine test (Fig. 3).
Saline infusion caused no changes in systolic and diastolic
blood pressure. Atenolol inhibited most of the increase in
systolic blood pressure, but there was still a significant
increase (P , 0.001). Diastolic blood pressure did not
change during dobutamine plus atenolol infusion.
Salbutamol test. Energy expenditure significantly
increased during salbutamol infusion (P , 0.001) and
remained at this level after the addition of atenolol
(Table 1). RER remained unchanged during the whole
test. Plasma glycerol and NEFA concentrations in-
creased significantly during salbutamol infusion (glyc-
erol: P , 0.01, NEFA: P , 0.001) and decreased after
the addition of atenolol (glycerol: P , 0.05, NEFA: P ,
0.001). However, plasma glycerol and NEFA levels
remained significantly higher with salbutamol plus
atenolol compared with baseline (both P , 0.01). Heart
rate and systolic blood pressure increased significantly
with salbutamol (both P , 0.001) and decreased signifi-
cantly after the addition of atenolol (heart rate: P ,
0.001, systolic blood pressure: P , 0.01). Heart rate
remained significantly higher during salbutamol plus
atenolol infusion compared with baseline (P , 0.001),
but systolic blood pressure did not differ from baseline
during salbutamol plus atenolol administration. Dia-
stolic blood pressure did not change during the test.
DISCUSSION
This study was performed to examine whether dobu-
tamine can be used as a selective b1-adrenoceptor
agonist in in vivo studies on human thermogenesis and
lipid utilization. Dobutamine induced significant in-
creases in energy expenditure, lipid oxidation, as mea-
sured by a decrease in RER, and lipolysis, as measured
by increases in plasma glycerol and NEFA levels. This
is in accordance with previous studies (2, 7).
From animal studies it is known that dobutamine
has significant a1- and b2-adrenoceptor-stimulating
properties at higher dosages in vitro (12, 13, 15, 16).
Furthermore, Daul et al. (5) showed that these adreno-
ceptors also play a role in the regulation of dobutamine-
induced changes in heart rate and blood pressure at
dosages of $6 µg·kg21 ·min21 in vivo in humans. We
intended to study the b1-adrenoceptor selectivity of
dobutamine for changes in thermogenesis and lipid
utilization. For that reason, b1-adrenoceptor-mediated
effects of dobutamine on energy expenditure, lipid
oxidation, and lipolysis were blocked with the selective
b1-adrenoceptor-antagonist atenolol. This design should
reveal all b2-adrenoceptor-mediated effects of dobuta-
mine, because a1-adrenoceptors play no role in human
thermogenesis (4, 6, 17). We found that atenolol com-
pletely inhibited the dobutamine-induced increases in
energy expenditure and plasma glycerol and NEFA
concentrations and the decrease in RER. These param-
eters remained at levels comparable with those during
the saline test, suggesting that dobutamine affects
these parameters only via b1-adrenoceptor stimulation
at the dosages used.
A control test was done to evaluate the selectivity for
b1- and b2-adrenoceptors of the dose of atenolol used.
b2-Adrenoceptor-mediated effects of salbutamol were
compared with those during simultaneous salbutamol
plus atenolol infusion. If atenolol blocks b2-adrenocep-
tors, all responses on salbutamol infusion should be
impaired after the addition of atenolol. We found that
salbutamol-induced changes in energy expenditure and
RER were not affected by atenolol. Thus it is unlikely
that the diminished increases in thermogenesis and
lipid oxidation during simultaneous dobutamine plus
atenolol infusion were due to b2-adrenoceptor blockade
by atenolol at the dosage used. This is also supported by
the fact that atenolol has an inhibition constant of 72
ng/ml for b1-adrenoceptors and 2,519 ng/ml for b2-
adrenoceptors (22). Thorne and Wahren (19) reported a
plasma atenolol concentration of ,300 ng/ml at a dose
of 1.67 µg·kg21 ·min21. This is comparable with a
plasma concentration of ,180 ng/ml for the dose of
atenolol we used (1.02 µg·kg21 ·min21). The affinity of
Table 1. Parameters at baseline, during salbutamol infusion, and during salbutamol plus atenolol infusion
Parameter Baseline
Salbutamol
(85 ng·kg21 ·min21)
Salbutamol Plus Atenolol
(1.02 µg·kg21 ·min21) ANOVA
Energy expenditure, kJ/min 5.4060.19 6.2060.14b 5.9560.20f ,0.001
Respiratory exchange ratio 0.8360.01 0.8260.01 0.8360.01 NS
Glycerol concentration, µmol/l 53.664.7 115.2614.2a 96.7613.1c,g ,0.001
NEFA concentration, µmol/l 249632 710675b 472665e,g ,0.001
Heart rate, beats/min 5662 7063b 6563e,h ,0.001
Systolic blood pressure, mmHg 11763 13063b 12164d ,0.001
Diastolic blood pressure, mmHg 6762 6162 6563 ,0.05
Values are means 6 SE; n 5 10 subjects. NEFA, nonesterified fatty acids; NS, not significant. Atenolol was bolus administered at 42.5 µg/kg.
Paired t-test: rest vs. salbutamol, aP , 0.01, bP , 0.001; salbutamol vs. salbutamol plus atenolol: cP , 0.05, dP , 0.01, eP , 0.001; rest vs.
salbutamol plus atenolol: fP , 0.05, gP , 0.01, hP , 0.001.
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salbutamol for b2- and b1-adrenoceptors lies only eight-
foldapart (8).Thissuggests thatconcomitant b1-adrenocep-
tor stimulation during salbutamol infusion is more
likely to have occurred than b2-adrenoceptor blockade
during simultaneous atenolol infusion. The significant
decreases in plasma glycerol and NEFA concentrations
after the addition of atenolol might therefore be due to
the blockade of the b1-adrenoceptor-mediated effects of
salbutamol. Another explanation might be that ateno-
lol blocked the basal b1-adrenoceptor-mediated effects
of the endogenous catecholamines on lipolysis.
It is still uncertain which processes are responsible
for sympathetically mediated thermogenesis and in
which tissues these processes are localized. Several
authors (9, 18) have suggested that the catecholamine-
induced increase in whole body energy expenditure
may partly be explained by the increase in myocardial
energy expenditure caused by an increase in cardiac
output. Myocardial energy expenditure can be esti-
mated by the rate-pressure product (heart rate 3
systolic blood pressure) (20). In our study, the esti-
mated increase in myocardial energy expenditure would
result in an overall increase in energy expenditure of
14% during the dobutamine test and of 2% during the
dobutamine plus atenolol test. Whole body energy
expenditure, however, increased 33% during the dobu-
tamine test and 5% during the dobutamine plus ateno-
lol infusion. The majority of the increase in energy
expenditure, therefore, appeared to result from sub-
strate oxidation in other tissues.
In summary, the results of this study indicate that, at
dosages of 2.5, 5, and 10 µg·kg21 ·min21, the predomi-
nantly b1-adrenoceptor agonist dobutamine caused sig-
nificant increases in energy expenditure, lipid oxida-
tion, and lipolysis. The b1-adrenoceptor-antagonist
atenolol blocked all dobutamine-induced increases in
thermogenesis and lipid utilization. All parameters
remained at levels comparable with those during saline
infusion. The dose of atenolol used was specific for
b1-adrenergic blockade and therefore did not camou-
flage concomitant b2-adrenoceptor stimulation by dobu-
tamine. Therefore, we conclude that dobutamine can be
used as selective b1-adrenoceptor agonist at dosages
#10 µg·kg21·min21 in in vivo studies on human thermo-
genesis and lipid utilization.
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